This once-a-day pill has the same active ingredient as Wegovy®** and empowers providers to tailor treatment plans specifically for those who prefer to avoid needles or need smaller doses to help to balance side-effects. This new option features a specialized formulation that is engineered to protect the active ingredient through digestion and support absorption. This new offering is part of our broader effort to help customers everywhere access personalized care to reach their weight loss goals, helping them achieve increased energy, better sleep, lower blood sugar, and improved mood.
As always, safety is our top priority. The Compounded Semaglutide Pill joins a wide range of other weight loss treatments accessible through our platform, all of which meet rigorous clinical standards. We adhere to all federal and state standards for compounding, and all active pharmaceutical ingredients (APIs) in compounded treatments are sourced exclusively from FDA-registered facilities.
This innovative offering is the result of eight years of robust investment in our pharmaceutical and fulfillment infrastructure. We doubled our facility footprint in 2025 to over one million square feet, including state-of-the-art pharmacy capabilities, lab testing services, and R&D space that will continue to support the next-generation personalized solutions we’ll bring to customers. This scale gives providers seamless access to the tools they need to individualize care across branded, generic, and compounded treatment options.
Our focus has always been to give customers access to the full benefit of every treatment available in the market, and we’re excited to find ways to partner with the companies behind the leading branded treatments, as well. More choice on the platform is the best thing for customers everywhere.
Our goal at Hims & Hers is simple: better outcomes through better access. As we continue to expand personalized weight loss care for millions of Americans, we are committed to helping every individual take control of their health and live better with confidence.
*Introductory pricing available to new, qualifying weight loss customers only. From $49 for the first month with a 5-month plan; remaining months at the standard $99 monthly price, paid upfront. Pricing varies by plan. Standard pricing applies after the intro period. Terms apply.
**Compounded drug products are not approved or evaluated for safety, effectiveness, or quality by the FDA. Available as part of a holistic weight loss treatment plan if prescribed by a provider after an online consultation. This compounded product uses a different formulation and delivery system than FDA-approved oral semaglutide.
Wegovy® is not compounded. Wegovy® is available as an injectable and oral pill and is FDA approved for weight loss. Wegovy® is a registered trademark of Novo Nordisk A/S. Hims, Inc. is not affiliated or endorsed by Novo Nordisk A/S.
Cautionary Note Regarding Forward-Looking Statements
This communication includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements can be identified by the use of forward-looking terminology, including the words “believes,” “estimates,” “anticipates,” “expects,” “intends,” “plans,” “assume,” “may,” “will,” “likely,” “potential,” “projects,” “predicts,” “continue,” “goal,” “strategy,” “future,” “forecast,” “target,” “step,” “outlook,” “opportunity,” “project,” "“confidence,” “foundation,” “groundwork,” “optimistic,” or “should,” or, in each case, their negative or other variations or comparable terminology. There can be no assurance that actual results will not materially differ from expectations. Such statements include, but are not limited to, statements regarding expanding customer choice, including with respect to branded GLP-1 offerings. These statements are based on management’s current expectations, but actual results may differ materially due to various factors.
Forward-looking statements are neither historical facts nor assurances of future performance. Instead, the forward-looking statements contained in this communication are based on our current expectations, assumptions and beliefs concerning future developments and their potential effects on us. Future developments affecting us may not be those that we have anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond our control) and other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, failure of our offering to perform as expected; the timing or feasibility of potential future collaborations or expanded access to branded treatment options; changes in healthcare, consumer protection or privacy laws; competitive product launches; higher than anticipated launch or marketing costs; shifts in consumer spending or behavior; and other factors described in the Risk Factors and other sections of our most recently filed Quarterly Report on Form 10-Q, our most recently filed Annual Report on Form 10-K, and other current and periodic reports we file from time to time with the Securities and Exchange Commission.
Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. The forward-looking statements contained in this communication are made only as of February 5, 2026. We undertake no obligation (and expressly disclaim any obligation) to update or revise any forward-looking statements, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. We caution you that forward-looking statements are not guarantees of future performance and that our actual results may differ materially from those made in or suggested by the forward-looking statements contained in this communication.
